Replimune Group, Inc. (REPL)
NASDAQ: REPL · Real-Time Price · USD
5.35
-3.28 (-38.01%)
At close: Jul 28, 2026, 4:00 PM EDT
5.44
+0.09 (1.68%)
Pre-market: Jul 29, 2026, 7:24 AM EDT
Replimune Group Employees
Replimune Group had 465 employees as of March 31, 2026. The number of employees decreased by 14 or -2.92% compared to the previous year.
Employees
465
Change (1Y)
-14
Growth (1Y)
-2.92%
Revenue / Employee
n/a
Profits / Employee
-$675,140
Market Cap
449.21M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 465 | -14 | -2.92% |
| Mar 31, 2025 | 479 | 148 | 44.71% |
| Mar 31, 2024 | 331 | 47 | 16.55% |
| Mar 31, 2023 | 284 | 78 | 37.86% |
| Mar 31, 2022 | 206 | 54 | 35.53% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 674 |
| ProKidney | 231 |
| Cabaletta Bio | 158 |
| Kyverna Therapeutics | 129 |
| Cybin | 100 |
| Prelude Therapeutics | 79 |
| Prothena Corporation | 67 |
| Inhibikase Therapeutics | 35 |
REPL News
- Just now - Replimune Group Proxy statement: Proxy filing - Filings
- Just now - Replimune Group Proxy statement: Proxy filing - Filings
- 13 hours ago - Replimune Group, Inc. (REPL) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel Following FDA Briefing Document - GlobeNewsWire
- 20 hours ago - BMO sees ‘uphill battle’ for Replimune at Thursday’s FDA panel meeting - TheFly
- 20 hours ago - Replimune sinks after FDA briefing documents question RP1 data - TheFly
- 23 hours ago - US FDA staff raise efficacy concerns on Replimune's skin cancer drug ahead of meeting - Reuters
- 1 day ago - Replimune Group put volume heavy and directionally bearish - TheFly
- 4 days ago - Replimune Group Registration statement: Registration filing - Filings